Canada-based psychedelic drug manufacturer Optimi Health intends to raise CAD 1.5 million (USD 1.1 million) through a non-brokered private placement for up to 5,000,000 units at CAD 0.3 per unit (USD 0.2 per unit).
These funds are earmarked for obtaining the company’s Drug Establishment License, commercialization, and general working capital.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.